Abeona Therapeutics Inc. (ABEO) - What Are Analysts Saying About This Stock?

Key Points

• Analysts maintain a Moderate Buy consensus on Abeona Therapeutics, with five buy ratings and one sell rating. The average 12-month price target is $21, with targets ranging from $17 to $30.
• Company insiders sold 56,906 shares worth approximately $306,160 over the past 90 days, primarily to cover tax obligations tied to vested equity awards. Institutional investors own 80.56% of the stock, with several firms recently increasing or initiating positions.
• ABEO opened at $4.90 and recently traded near the lower end of its 52-week range. The company reported a quarterly loss of $0.35 per share, missing the $0.23 consensus estimate, while revenue of $11.38 million also fell short of expectations.

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $21.00.

Several brokerages have recently commented on ABEO. Weiss Ratings lowered Abeona Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday, August 17th. Oppenheimer reaffirmed an "outperform" rating and set a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Roth Capital started coverage on Abeona Therapeutics in a report on Thursday, September 17th. They set a "buy" rating and a $17.00 price objective for the company. UBS Group reiterated a "buy" rating on shares of Abeona Therapeutics in a report on Friday, September 25th. Finally, Cantor Fitzgerald raised their price objective on Abeona Therapeutics from $28.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, September 18th.

Insiders Place Their Bets

In related news, CEO Vishwas Seshadri sold 19,608 shares of the company's stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total transaction of $101,177.28. Following the completion of the sale, the chief executive officer directly owned 1,286,500 shares of the company's stock, valued at approximately $6,638,340. This represents a 1.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Joseph Vazzano sold 9,191 shares of the stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total value of $47,425.56. Following the completion of the sale, the chief financial officer owned 482,888 shares of the company's stock, valued at approximately $2,491,702.08. This represents a 1.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 56,906 shares of company stock worth $306,160. 7.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. AWM Investment Company Inc. acquired a new position in Abeona Therapeutics during the 2nd quarter worth approximately $9,184,000. AIGH Capital Management LLC grew its position in Abeona Therapeutics by 55.0% in the first quarter. AIGH Capital Management LLC now owns 3,100,000 shares of the biopharmaceutical company's stock valued at $13,888,000 after acquiring an additional 1,100,000 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $1,262,000. Sei Investments Co. grew its position in Abeona Therapeutics by 142.4% in the first quarter. Sei Investments Co. now owns 172,460 shares of the biopharmaceutical company's stock valued at $773,000 after acquiring an additional 101,307 shares in the last quarter. Finally, Corient Private Wealth LP purchased a new stake in shares of Abeona Therapeutics during the second quarter valued at approximately $556,000. Hedge funds and other institutional investors own 80.56% of the company's stock.

Abeona Therapeutics Trading Down 0.8%

Shares of Abeona Therapeutics stock opened at $4.90 on Tuesday. The firm has a market cap of $280.18 million, a price-to-earnings ratio of -4.50 and a beta of 1.31. Abeona Therapeutics has a 52-week low of $4.00 and a 52-week high of $7.65. The company's 50-day simple moving average is $5.84 and its 200-day simple moving average is $5.75. The company has a quick ratio of 6.40, a current ratio of 6.63 and a debt-to-equity ratio of 0.01.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.12). The company had revenue of $11.38 million for the quarter, compared to analysts' expectations of $12.24 million. As a group, equities research analysts anticipate that Abeona Therapeutics will post -0.88 earnings per share for the current year.

About Abeona Therapeutics

Abeona Therapeutics Inc is a biotechnology company focused on developing and commercializing cell and gene therapies for serious diseases. The company's primary focus is regenerative medicine, with an emphasis on treatments that address rare genetic disorders and conditions involving damaged or absent tissue.

Abeona's lead product, ZEVASKYN (prademagene zamikeracel, formerly EB-101), is an autologous, gene-corrected cell therapy for wounds associated with recessive dystrophic epidermolysis bullosa (RDEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.